GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2013

Janssen Licenses Amunix' Half-Life Extension Technology

  • Amunix struck a worldwide research collaboration and licensing deal with Janssen Biotech. Amunix will combine its XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen.

    Amunix will assist Janssen in engineering up to three XTEN fusion proteins. Janssen will be responsible for all preclinical and clinical development as well as for manufacturing and commercialization of the resulting products. Amunix will receive an initial up-front payment in addition to R&D funding and will be eligible for future milestone and royalty payments.

    “Amunix’ XTEN polymer can be combined with a range of proteins and peptides,” says Volker Schellenberger, Ph.D., president of Amunix. “Collaborations such as this are a central element of our strategy to facilitate the use of XTEN in a range of therapeutic applications.”

    In recent years, Amunix has invested in two young firms—Versartis and Diartis—to exploit its XTEN technology. The XTEN platform comprises a long, hydrophilic, unstructured polyamino acid tail, expressed as a fusion protein with the therapeutically active peptide or protein. Amunix says XTEN addresses the manufacturing and safety issues associated with the conjugation steps required in current PEGylation approaches, and could reduce the cost of goods by almost 10-fold relative to PEGylation.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »